{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:27:47Z","timestamp":1760984867042,"version":"build-2065373602"},"reference-count":162,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.soc.2013.06.012","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T22:20:53Z","timestamp":1374790853000},"page":"857-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Translational Research in Endocrine Surgery"],"prefix":"10.1016","volume":"22","author":[{"given":"Scott K.","family":"Sherman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2013.06.012_bib1","doi-asserted-by":"crossref","first-page":"E898","DOI":"10.1210\/jc.2011-3269","article-title":"Activation of the RAS\/RAF\/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines","volume":"97","author":"Piscazzi","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.soc.2013.06.012_bib3","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1158\/1078-0432.CCR-11-1155","article-title":"Role of BRAF in thyroid oncogenesis","volume":"17","author":"Caronia","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.soc.2013.06.012_bib5","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/thy.2007.0357","article-title":"Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways","volume":"18","author":"Liu","year":"2008","journal-title":"Thyroid"},{"key":"10.1016\/j.soc.2013.06.012_bib6","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1210\/en.2006-0400","article-title":"BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation","volume":"147","author":"Palona","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.soc.2013.06.012_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/annonc\/mdr117","article-title":"New treatment modalities in advanced thyroid cancer","volume":"23","author":"Kapiteijn","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib8","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/cncr.25061","article-title":"Genetic alterations in the RAS\/RAF\/mitogen-activated protein kinase and phosphatidylinositol 3-kinase\/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma","volume":"116","author":"Santarpia","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib9","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MD.0b013e31826a9c71","article-title":"BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis","volume":"91","author":"Tufano","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.soc.2013.06.012_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ceb.2009.01.013","article-title":"Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets","volume":"21","author":"Knauf","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.soc.2013.06.012_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/328527a0","article-title":"A\u00a0linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10","volume":"328","author":"Mathew","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/328528a0","article-title":"Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage","volume":"328","author":"Simpson","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0888-7543(91)90237-9","article-title":"Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A","volume":"9","author":"Lairmore","year":"1991","journal-title":"Genomics"},{"key":"10.1016\/j.soc.2013.06.012_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/328170a0","article-title":"A\u00a0new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases","volume":"328","author":"Fusco","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib17","first-page":"521","article-title":"The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A)","volume":"4","author":"Donghi","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.soc.2013.06.012_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in\u00a0vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib19","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1073\/pnas.89.5.1616","article-title":"Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET\/PTC","volume":"89","author":"Pierotti","year":"1992","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.soc.2013.06.012_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1073\/pnas.90.2.492","article-title":"A\u00a01.5-megabase yeast artificial chromosome contig from human chromosome 10q11.2 connecting three genetic loci (RET, D10S94, and D10S102) closely linked to the MEN2A locus","volume":"90","author":"Lairmore","year":"1993","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.soc.2013.06.012_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A\u00a0mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/hmg\/3.2.237","article-title":"Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours","volume":"3","author":"Eng","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.91.4.1579","article-title":"Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.soc.2013.06.012_bib26","first-page":"124","article-title":"Predictive testing for multiple endocrine neoplasia type 2A (MEN 2A) based on the detection of mutations in the RET protooncogene","volume":"116","author":"Chi","year":"1994","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2013.06.012_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000658-199409000-00002","article-title":"Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A","volume":"220","author":"Wells","year":"1994","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng0194-70","article-title":"Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC","volume":"6","author":"Mulligan","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib29","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.soc.2013.06.012_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3468(96)90343-7","article-title":"Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B","volume":"31","author":"Skinner","year":"1996","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib31","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.soc.2013.06.012_bib33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1245\/s10434-009-0524-3","article-title":"When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?","volume":"16","author":"Calva","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jpsu.2002.32906","article-title":"Multiple endocrine neoplasia 2A syndrome: surgical management","volume":"37","author":"Simon","year":"2002","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib35","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib36","doi-asserted-by":"crossref","first-page":"E364","DOI":"10.1210\/jc.2012-2703","article-title":"Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS","volume":"98","author":"Agrawal","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib39","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","article-title":"BRAF mutation in papillary thyroid carcinoma","volume":"95","author":"Cohen","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2013.06.012_bib41","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-06-1753","article-title":"Suppression of BRAF\/MEK\/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib42","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-04-3314","article-title":"Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells","volume":"65","author":"Mitsutake","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib44","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1530\/ERC-11-0076","article-title":"BRAFV600E mutation, TIMP-1 upregulation, and NF-kappaB activation: closing the loop on the papillary thyroid cancer trilogy","volume":"18","author":"Bommarito","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib45","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.sla.0000224751.80858.13","article-title":"Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma","volume":"244","author":"Kim","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib47","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2008.20.1426","article-title":"BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer","volume":"27","author":"Xing","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2265.2006.02605.x","article-title":"The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma","volume":"65","author":"Kim","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.soc.2013.06.012_bib49","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.surg.2012.08.039","article-title":"BRAF(V600E) status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence","volume":"152","author":"Prescott","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2013.06.012_bib50","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/cncr.26425","article-title":"A\u00a0combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma","volume":"118","author":"Niemeier","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jso.21234","article-title":"The role of lymphadenectomy in the management of papillary carcinoma of the thyroid","volume":"99","author":"Rotstein","year":"2009","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib52","article-title":"Braf, a tool in the decision to perform elective neck dissection?","author":"Dutenhefner","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.soc.2013.06.012_bib53","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1210\/jc.2012-2444","article-title":"Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study","volume":"97","author":"Joo","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib54","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib56","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib57","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-07-1772","article-title":"Sorafenib potently inhibits papillary thyroid carcinomas harboring RET\/PTC1 rearrangement","volume":"14","author":"Henderson","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.soc.2013.06.012_bib58","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.soc.2013.06.012_bib59","article-title":"An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline","volume":"30","author":"Shoffski","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2010-0317","article-title":"Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer","volume":"16","author":"Nucera","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.soc.2013.06.012_bib61","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.surg.2010.09.001","article-title":"Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer","volume":"148","author":"Nehs","year":"2010","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2013.06.012_bib62","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1210\/en.2011-1519","article-title":"Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer","volume":"153","author":"Nehs","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.soc.2013.06.012_bib63","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMc1215697","article-title":"BRAF V600E inhibition in anaplastic thyroid cancer","volume":"368","author":"Rosove","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib64","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2013.06.012_bib65","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1158\/1078-0432.CCR-12-1253","article-title":"New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers","volume":"19","author":"Nikiforov","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jamcollsurg.2012.05.027","article-title":"Intraoperative pathologic examination in the era of molecular testing for differentiated thyroid cancer","volume":"215","author":"McCoy","year":"2012","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib67","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1126\/science.289.5483.1357","article-title":"PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]","volume":"289","author":"Kroll","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/CBM-2012-0273","article-title":"The value of miRNA in diagnosing thyroid cancer: a systematic review","volume":"11","author":"Lodewijk","year":"2012","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.soc.2013.06.012_bib69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1203208","article-title":"Preoperative diagnosis of benign thyroid nodules with indeterminate cytology","volume":"367","author":"Alexander","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib70","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1089\/thy.2012.0180","article-title":"The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology","volume":"22","author":"Duick","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.soc.2013.06.012_bib71","doi-asserted-by":"crossref","first-page":"E1719","DOI":"10.1210\/jc.2011-0459","article-title":"Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules","volume":"96","author":"Li","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.30_suppl.58","article-title":"Criteria for use of omics-based predictors in NCI-sponsored clinical trials","volume":"30","author":"McShane","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib73","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jc.2011-1469","article-title":"Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples","volume":"96","author":"Nikiforov","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib74","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng1048","article-title":"HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome","volume":"32","author":"Carpten","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib75","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa031237","article-title":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma","volume":"349","author":"Shattuck","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib76","first-page":"275802","article-title":"Molecular alterations in sporadic primary hyperparathyroidism","volume":"2011","author":"Alvelos","year":"2011","journal-title":"Genet Res Int"},{"key":"10.1016\/j.soc.2013.06.012_bib77","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cell.2006.01.053","article-title":"Parafibromin\/Hyrax activates Wnt\/Wg target gene transcription by direct association with beta-catenin\/Armadillo","volume":"125","author":"Mosimann","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib78","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1158\/1078-0432.CCR-04-0493","article-title":"Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma","volume":"10","author":"Tan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib79","doi-asserted-by":"crossref","first-page":"324964","DOI":"10.1155\/2010\/324964","article-title":"Parafibromin as a diagnostic instrument for parathyroid carcinoma\u2014Lone Ranger or part of the posse?","volume":"2010","author":"Juhlin","year":"2010","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.soc.2013.06.012_bib80","first-page":"1070","article-title":"Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up","volume":"114","author":"Howe","year":"1993","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2013.06.012_bib81","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/humu.21385","article-title":"Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10","volume":"32","author":"Frank-Raue","year":"2011","journal-title":"Hum Mutat"},{"key":"10.1016\/j.soc.2013.06.012_bib82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/332085a0","article-title":"Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma","volume":"332","author":"Larsson","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.soc.2013.06.012_bib83","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib84","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","article-title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1","volume":"6","author":"Lemmens","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.seminoncol.2012.11.005","article-title":"The genetics of neuroendocrine tumors","volume":"40","author":"Oberg","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/humu.20605","article-title":"Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene","volume":"29","author":"Lemos","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.soc.2013.06.012_bib87","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib88","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.sla.0000124383.98416.8d","article-title":"Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1)","volume":"239","author":"Lairmore","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib89","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.suc.2009.06.016","article-title":"Surgical management of MEN-1 and -2: state of the art","volume":"89","author":"Akerstrom","year":"2009","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.soc.2013.06.012_bib90","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/bjs.7154","article-title":"Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism","volume":"97","author":"Waldmann","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib91","doi-asserted-by":"crossref","first-page":"E1774","DOI":"10.1210\/jc.2012-1743","article-title":"Identification of somatic mutations in parathyroid tumors using whole-exome sequencing","volume":"97","author":"Cromer","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2012.01.009","article-title":"Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background","volume":"205","author":"Fishbein","year":"2012","journal-title":"Cancer Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib93","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/jmg.24.9.536","article-title":"A\u00a0genomic search for linkage of neurofibromatosis to RFLPs","volume":"24","author":"Barker","year":"1987","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib94","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0092-8674(87)90534-4","article-title":"Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene","volume":"49","author":"Seizinger","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib95","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2006-2833","article-title":"Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1","volume":"92","author":"Bausch","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib96","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1093\/hmg\/dds402","article-title":"Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas","volume":"21","author":"Welander","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib97","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","article-title":"The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21","volume":"63","author":"Martin","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.soc.2013.06.012_bib98","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.soc.2013.06.012_bib99","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00000658-199802000-00012","article-title":"Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors","volume":"227","author":"Curley","year":"1998","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib101","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"Ong","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.soc.2013.06.012_bib103","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib104","first-page":"6822","article-title":"Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma","volume":"60","author":"Gimm","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib105","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(00)04378-6","article-title":"Germline SDHD mutation in familial phaeochromocytoma","volume":"357","author":"Astuti","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2013.06.012_bib106","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1038\/sj.onc.1207591","article-title":"Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families","volume":"23","author":"Hensen","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.soc.2013.06.012_bib107","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","article-title":"SDHA is a tumor suppressor gene causing paraganglioma","volume":"19","author":"Burnichon","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/321282","article-title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma","volume":"69","author":"Astuti","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib109","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/81551","article-title":"Mutations in SDHC cause autosomal dominant paraganglioma, type 3","volume":"26","author":"Niemann","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib110","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","article-title":"SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma","volume":"325","author":"Hao","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib111","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(10)70007-3","article-title":"SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma","volume":"11","author":"Bayley","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib112","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/ERC-11-0170","article-title":"Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas","volume":"18","author":"Welander","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib113","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1677\/ERC-08-0284","article-title":"Clinical aspects of SDHx-related pheochromocytoma and paraganglioma","volume":"16","author":"Timmers","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib114","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib116","doi-asserted-by":"crossref","first-page":"E805","DOI":"10.1210\/jc.2011-3360","article-title":"TMEM127 screening in a large cohort of patients with pheochromocytoma and\/or paraganglioma","volume":"97","author":"Abermil","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib117","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib118","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2013.06.012_bib119","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib120","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib121","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","article-title":"Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis","volume":"162","author":"Giordano","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.soc.2013.06.012_bib122","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/jmedgenet-2012-100967","article-title":"Clinical significance of copy number variations in the 11p15.5 imprinting control regions: new cases and review of the literature","volume":"49","author":"Begemann","year":"2012","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib123","first-page":"1444","article-title":"Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors","volume":"78","author":"Gicquel","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.tem.2012.04.001","article-title":"The next generation of therapies for adrenocortical cancers","volume":"23","author":"Kirschner","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib125","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1210\/jc.2004-1075","article-title":"Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy","volume":"90","author":"de Fraipont","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib126","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib127","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib128","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.surg.2012.08.035","article-title":"Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma","volume":"152","author":"Lin","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2013.06.012_bib129","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.soc.2013.06.012_bib130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.soc.2013.06.012_bib131","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/HYPERTENSIONAHA.111.186478","article-title":"Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism","volume":"59","author":"Boulkroun","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.soc.2013.06.012_bib132","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib133","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.sla.0000197715.96762.68","article-title":"Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas","volume":"243","author":"Triponez","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib134","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1067\/msy.1998.92561","article-title":"Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size","volume":"124","author":"Lowney","year":"1998","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.soc.2013.06.012_bib135","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry","volume":"49","author":"Korse","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib136","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib137","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0140-6736(79)92115-9","article-title":"Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue","volume":"2","author":"Long","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2013.06.012_bib138","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1530\/eje.1.02307","article-title":"The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies","volume":"155","author":"O'Toole","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.soc.2013.06.012_bib139","unstructured":"Sherman SK, Carr JC, Wang D, et\u00a0al. Gastric inhibitory polypeptide receptor is a promising target for imaging and therapy in neuroendocrine tumors. Surgery, in press."},{"key":"10.1016\/j.soc.2013.06.012_bib140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1073\/pnas.89.1.251","article-title":"Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney","volume":"89","author":"Yamada","year":"1992","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.soc.2013.06.012_bib141","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","article-title":"Molecular imaging with (6)(8)Ga-SSTR PET\/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours","volume":"38","author":"Kaemmerer","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.soc.2013.06.012_bib142","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.pharmthera.2007.06.010","article-title":"An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology","volume":"116","author":"Cervia","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.soc.2013.06.012_bib143","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1385\/MO:21:3:285","article-title":"Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells","volume":"21","author":"Ludvigsen","year":"2004","journal-title":"Med Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.soc.2013.06.012_bib144","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib145","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib146","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib147","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.soc.2013.06.012_bib148","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1245\/s10434-012-2836-y","article-title":"The value of preoperative imaging in small bowel neuroendocrine tumors","volume":"20","author":"Dahdaleh","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2013.06.012_bib149","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.soc.2013.06.012_bib150","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib151","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199210013271402","article-title":"Gastric inhibitory polypeptide-dependent cortisol hypersecretion\u2014a new cause of Cushing's syndrome","volume":"327","author":"Lacroix","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib152","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrgastro.2012.9","article-title":"Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy","volume":"9","author":"de Wilde","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.soc.2013.06.012_bib153","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib154","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.soc.2013.06.012_bib155","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/sj.onc.1205058","article-title":"Alternative lengthening of telomeres in mammalian cells","volume":"21","author":"Henson","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.soc.2013.06.012_bib156","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib157","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2013.06.012_bib158","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jjco\/27.3.128","article-title":"A\u00a0nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan","volume":"27","author":"Iihara","year":"1997","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.soc.2013.06.012_bib159","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/jc.2005-0064","article-title":"Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2","volume":"90","author":"Machens","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.soc.2013.06.012_bib160","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archsurg.138.4.409","article-title":"Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship","volume":"138","author":"Yip","year":"2003","journal-title":"Arch Surg"},{"key":"10.1016\/j.soc.2013.06.012_bib161","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cncr.23648","article-title":"Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies","volume":"113","author":"Jensen","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2013.06.012_bib162","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmed.2012.11.001","article-title":"mTOR: on target for novel therapeutic strategies in the nervous system","volume":"19","author":"Maiese","year":"2013","journal-title":"Trends Mol Med"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532071300063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532071300063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:00:27Z","timestamp":1760961627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105532071300063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":162,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S105532071300063X"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2013.06.012","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational Research in Endocrine Surgery","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2013.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}